Veru reports Q3 FY2026 net loss $7.0M; PLATEAU trial fully enrolled with 239 patients

VERU INC.

Q3 net loss $7.0M ($0.30/share) vs $7.3M ($0.50/share) prior year; operating loss $7.7M.
Phase 2b PLATEAU fully enrolled with 239 patients (target 200); interim analysis Q1 2027, final topline Q4 2027.
USPTO notice of allowance for enobosarm+semaglutide patent; protection until at least Oct 2044.
Clinical supply agreement with Novo Nordisk for PLATEAU trial announced June 2026.
Cash $23.9M at June 30, 2026 vs $15.8M at Sept 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.